Clinical Trials Logo

Central Precocious Puberty clinical trials

View clinical trials related to Central Precocious Puberty.

Filter by:

NCT ID: NCT06129539 Recruiting - Clinical trials for Central Precocious Puberty

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty

LIBELULA
Start date: July 2024
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of Debio 4326 in suppressing serum luteinizing hormone (LH) to prepubertal levels 52 weeks after the first Debio 4326 injection in pediatric participants receiving gonadotropin-releasing hormone agonist (GnRHa) therapy for central precocious puberty (CPP).

NCT ID: NCT06025409 Recruiting - Clinical trials for Central Precocious Puberty

Evaluate the Efficacy and Safety of DWJ108J

Start date: August 1, 2023
Phase: Phase 3
Study type: Interventional

This study aims to evaluate the efficacy and safety of DWJ108J (Leuprorelin acetate 11.25 mg) in patients with central precocious puberty.

NCT ID: NCT05341128 Not yet recruiting - Clinical trials for Central Precocious Puberty

A Study of Medical Records From Children With Central Precocious Puberty (CPP) in China

Start date: May 31, 2025
Phase:
Study type: Observational

The main purpose is to describe how many children were treated during 24 months or less because of CPP and how treatment worked for them. There are no participants in this trial, the study only involves reviewing participants medical past and current records and collecting information.

NCT ID: NCT05341115 Recruiting - Clinical trials for Central Precocious Puberty

A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty

Start date: March 14, 2023
Phase: Phase 4
Study type: Interventional

The main aim is to see how leuprolide works to treat central precocious puberty in children. Participants will receive an injection of leuprorelin acetate depot 11.25 mg every 12 weeks during 6 months and will visit their study clinic 6 times to complete some assessments.

NCT ID: NCT05029622 Completed - Clinical trials for Central Precocious Puberty

A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.

Start date: August 10, 2021
Phase: Phase 3
Study type: Interventional

The purpose of the protocol is to assess the efficacy of the triptorelin 6 month PR (Prolonged Release) formulation in suppressing LH (Luteinising hormone) levels to prepubertal levels (defined as a peak LH ≤5 IU/L) after i.v. GnRH (Gonadotropin-releasing Hormone) stimulation at Month 6 (Day 169) in Chinese children with CPP (Central Precocious Puberty).

NCT ID: NCT04736602 Completed - Clinical trials for Central Precocious Puberty

Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.

Start date: March 27, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to observe whether the Triptorelin pamoate 15mg (3-month formulation) effectiveness in Chinese population of CPP children has the same or similar trend with that in overseas CPP population. This is measured by assessing the proportion of children who have a suppressed Luteinizing Hormone (LH) response to Gonadotropin Releasing Hormone (GnRH) test performed 3 months after injection of triptorelin.

NCT ID: NCT03316482 Completed - Clinical trials for Central Precocious Puberty

Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty

Start date: June 11, 2015
Phase: Phase 4
Study type: Interventional

A multicenter, open-label, prospective study to evaluate the safety and efficacy of leuprorelin acetate DPS (Leuplin DPS) treatment quarterly in patients with central precocious puberty

NCT ID: NCT02993926 Completed - Clinical trials for Central Precocious Puberty

A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants

Start date: June 24, 2017
Phase:
Study type: Observational

The purpose of this study is to evaluate the long-term safety and efficacy of Enantone in the treatment of CPP in Chinese participants.

NCT ID: NCT02920515 Completed - Clinical trials for Central Precocious Puberty

Study of Comprehensive Diagnosis and Treatment for Children Precocious Puberty

Start date: September 2012
Phase: Phase 4
Study type: Interventional

This is a prospective, multicentric, comparative, non-randomized interventional study in which subjects diagnosed with central precocious puberty (CPP) and early puberty (EP) were treated for 6 months to compare the effect with GnRHa and traditional Chinese medicines.

NCT ID: NCT02811471 Recruiting - Clinical trials for Central Precocious Puberty

Pharmacokinetic Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty

Start date: June 2016
Phase: Phase 3
Study type: Interventional

Exploring the efficacy in Leuprolide 45mg in slowing down or reversing Central Precocious Puberty in girls ages 2-8 and boys ages 2-9.